TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Core Insights - TG Therapeutics, Inc. announced the presentation schedule for data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial for BRIUMVI in patients with relapsing forms of multiple sclerosis (RMS) at the ACTRIMS annual forum from February 27 to March 1, 2025 [1][2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI being approved for RMS treatment in the U.S., Europe, and the UK [24] - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to enhance B-cell depletion through glycoengineering [5][6] Clinical Trials - The ULTIMATE I & II trials are randomized, double-blind studies involving 1,094 RMS patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - The ENHANCE trial focuses on the safety and tolerability of 30-minute BRIUMVI infusions and evaluates Fc biology and genetic diversity in MS [2][3] Presentation Details - Presentations will include topics such as real-world experiences with BRIUMVI and disease activity trajectories in the ULTIMATE trials [2][4] - Specific presentation dates and authors have been outlined for the ACTRIMS forum [4]